Association of plasma resistin levels with coronary heart disease in women

Obesity Research

Volumn 13, Issue 10, 2005, Pages 1764-1771

  Pischon, Tobias ^a   Bamberger, Christoph M ^b   Kratzsch, Jürgen ^c   Zyriax, Birgit Christiane ^b   Algenstaedt, Petra ^b   Boeing, Heiner ^a   Windler, Eberhard ^b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adipokine; Coronary heart disease; Epidemiology; Inflammation; Risk factor

Indexed keywords

RESISTIN;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MIDDLE AGED; RESISTIN;

EID: 33644803429     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.215     Document Type: Article

References (34)

1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12.
2. Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98:502-6.
3. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor gamma agonists. J Biol Chem. 2001;276:25651-3.
4. Fujita H, Fujishima H, Morii T, et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun. 2002;298:345-9.
5. Fukui Y, Motojima K. Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor alpha. Diabetes Obes Metab. 2002;4:342-5.
6. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111:225-30.
7. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199-202.
8. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun. 2001;285:561-4.
9. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res. 2002;10:1-5.
10. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88:5452-5.
11. Azuma K, Katsukawa F, Oguchi S, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:997-1001.
12. Fujinami A, Obayashi H, Ohta K, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta. 2004;339:57-63.
13. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88:4848-56.
14. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149:331-5.
15. Silha JV, Krsek M, Skrha J, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, leptin and adiponectin levels in non-diabetic and diabetic obese subjects. Diabet Med. 2004; 21:497-9.
16. Silha JV, Murphy LJ. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2004;89:1977; author reply 1978.
17. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730-6.
18. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab. 2003;49:571-6.
19. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000;19:4046-55.
20. Gomez-Ambrosi J, Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern. Med. 2001;135:306-7.
21. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
22. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736-40.
23. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415-9.
24. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322:213-7.
25. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332:1758-66.
26. Schulze MB, Kroke A, Saracci R, Boeing H. The effect of differences in measurement procedure on the comparability of blood pressure estimates in multi-centre studies. Blood Press Monit. 2002;7:95-104.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
30. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
31. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
32. Schaffler A, Buchler C, Muller-Ladner U, et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Harm Metab Res. 2004;36:702-7.
33. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27:2450-7.
34. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-94.